Increased risk of cancer in patients with fumarate hydratase germline mutation

H. J. Lehtonen, Maija Ht Kiuru, S. K. Ylisaukko-Oja, R. Salovaara, R. Herva, P. A. Koivisto, O. Vierimaa, K. Aittomäki, E. Pukkala, V. Launonen, L. A. Aaltonen

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumour predisposition syndrome caused by heterozygous germline mutations in the fumarate hydratase (FH) gene. The condition is characterised by predisposition to benign leiomyomas of the skin and the uterus, renal cell carcinoma (RCC), and uterine leiomyosarcoma (ULMS). To comprehensively examine the cancer risk and tumour spectrum in Finnish FH mutation positive families, genealogical and cancer data were obtained from 868 individuals. The cohort analysis of the standardised incidence ratios (SIR) was analysed from 256 individuals. FH mutation status was analysed from all available individuals (n = 98). To study tumour spectrum in FH mutation carriers, loss of the wild type allele was analysed from all available tumours (n = 22). The SIR was 6.5 for RCC and 71 for ULMS. The overall cancer risk was statistically significantly increased in the age group of 15-29 years, consistent with features of cancer predisposition families in general. FH germline mutation was found in 55% of studied individuals. Most RCC and ULMS tumours displayed biallelic inactivation of FH, as did breast and bladder cancers. In addition, several benign tumours including atypical uterine leiomyomas, kidney cysts, and adrenal gland adenomas were observed. The present study confirms with calculated risk ratios the association of early onset RCC and ULMS with FH germline mutations in Finns. Some evidence for association of breast and bladder carcinoma with HLRCC was obtained. The data enlighten the organ specific malignant potential of HLRCC.

Original languageEnglish (US)
Pages (from-to)523-526
Number of pages4
JournalJournal of Medical Genetics
Volume43
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Fumarate Hydratase
Germ-Line Mutation
Leiomyosarcoma
Neoplasms
Renal Cell Carcinoma
Leiomyoma
Mutation
Breast Neoplasms
Incidence
Adrenal Glands
Urinary Bladder Neoplasms
Adenoma
Uterus
Cysts
Urinary Bladder
Cohort Studies
Age Groups
Alleles
Odds Ratio

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Lehtonen, H. J., Kiuru, M. H., Ylisaukko-Oja, S. K., Salovaara, R., Herva, R., Koivisto, P. A., ... Aaltonen, L. A. (2006). Increased risk of cancer in patients with fumarate hydratase germline mutation. Journal of Medical Genetics, 43(6), 523-526. https://doi.org/10.1136/jmg.2005.036400

Increased risk of cancer in patients with fumarate hydratase germline mutation. / Lehtonen, H. J.; Kiuru, Maija Ht; Ylisaukko-Oja, S. K.; Salovaara, R.; Herva, R.; Koivisto, P. A.; Vierimaa, O.; Aittomäki, K.; Pukkala, E.; Launonen, V.; Aaltonen, L. A.

In: Journal of Medical Genetics, Vol. 43, No. 6, 06.2006, p. 523-526.

Research output: Contribution to journalArticle

Lehtonen, HJ, Kiuru, MH, Ylisaukko-Oja, SK, Salovaara, R, Herva, R, Koivisto, PA, Vierimaa, O, Aittomäki, K, Pukkala, E, Launonen, V & Aaltonen, LA 2006, 'Increased risk of cancer in patients with fumarate hydratase germline mutation', Journal of Medical Genetics, vol. 43, no. 6, pp. 523-526. https://doi.org/10.1136/jmg.2005.036400
Lehtonen, H. J. ; Kiuru, Maija Ht ; Ylisaukko-Oja, S. K. ; Salovaara, R. ; Herva, R. ; Koivisto, P. A. ; Vierimaa, O. ; Aittomäki, K. ; Pukkala, E. ; Launonen, V. ; Aaltonen, L. A. / Increased risk of cancer in patients with fumarate hydratase germline mutation. In: Journal of Medical Genetics. 2006 ; Vol. 43, No. 6. pp. 523-526.
@article{d615a9b2e35f486d97518a8d0ca4a792,
title = "Increased risk of cancer in patients with fumarate hydratase germline mutation",
abstract = "Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumour predisposition syndrome caused by heterozygous germline mutations in the fumarate hydratase (FH) gene. The condition is characterised by predisposition to benign leiomyomas of the skin and the uterus, renal cell carcinoma (RCC), and uterine leiomyosarcoma (ULMS). To comprehensively examine the cancer risk and tumour spectrum in Finnish FH mutation positive families, genealogical and cancer data were obtained from 868 individuals. The cohort analysis of the standardised incidence ratios (SIR) was analysed from 256 individuals. FH mutation status was analysed from all available individuals (n = 98). To study tumour spectrum in FH mutation carriers, loss of the wild type allele was analysed from all available tumours (n = 22). The SIR was 6.5 for RCC and 71 for ULMS. The overall cancer risk was statistically significantly increased in the age group of 15-29 years, consistent with features of cancer predisposition families in general. FH germline mutation was found in 55{\%} of studied individuals. Most RCC and ULMS tumours displayed biallelic inactivation of FH, as did breast and bladder cancers. In addition, several benign tumours including atypical uterine leiomyomas, kidney cysts, and adrenal gland adenomas were observed. The present study confirms with calculated risk ratios the association of early onset RCC and ULMS with FH germline mutations in Finns. Some evidence for association of breast and bladder carcinoma with HLRCC was obtained. The data enlighten the organ specific malignant potential of HLRCC.",
author = "Lehtonen, {H. J.} and Kiuru, {Maija Ht} and Ylisaukko-Oja, {S. K.} and R. Salovaara and R. Herva and Koivisto, {P. A.} and O. Vierimaa and K. Aittom{\"a}ki and E. Pukkala and V. Launonen and Aaltonen, {L. A.}",
year = "2006",
month = "6",
doi = "10.1136/jmg.2005.036400",
language = "English (US)",
volume = "43",
pages = "523--526",
journal = "Journal of Medical Genetics",
issn = "0022-2593",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Increased risk of cancer in patients with fumarate hydratase germline mutation

AU - Lehtonen, H. J.

AU - Kiuru, Maija Ht

AU - Ylisaukko-Oja, S. K.

AU - Salovaara, R.

AU - Herva, R.

AU - Koivisto, P. A.

AU - Vierimaa, O.

AU - Aittomäki, K.

AU - Pukkala, E.

AU - Launonen, V.

AU - Aaltonen, L. A.

PY - 2006/6

Y1 - 2006/6

N2 - Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumour predisposition syndrome caused by heterozygous germline mutations in the fumarate hydratase (FH) gene. The condition is characterised by predisposition to benign leiomyomas of the skin and the uterus, renal cell carcinoma (RCC), and uterine leiomyosarcoma (ULMS). To comprehensively examine the cancer risk and tumour spectrum in Finnish FH mutation positive families, genealogical and cancer data were obtained from 868 individuals. The cohort analysis of the standardised incidence ratios (SIR) was analysed from 256 individuals. FH mutation status was analysed from all available individuals (n = 98). To study tumour spectrum in FH mutation carriers, loss of the wild type allele was analysed from all available tumours (n = 22). The SIR was 6.5 for RCC and 71 for ULMS. The overall cancer risk was statistically significantly increased in the age group of 15-29 years, consistent with features of cancer predisposition families in general. FH germline mutation was found in 55% of studied individuals. Most RCC and ULMS tumours displayed biallelic inactivation of FH, as did breast and bladder cancers. In addition, several benign tumours including atypical uterine leiomyomas, kidney cysts, and adrenal gland adenomas were observed. The present study confirms with calculated risk ratios the association of early onset RCC and ULMS with FH germline mutations in Finns. Some evidence for association of breast and bladder carcinoma with HLRCC was obtained. The data enlighten the organ specific malignant potential of HLRCC.

AB - Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumour predisposition syndrome caused by heterozygous germline mutations in the fumarate hydratase (FH) gene. The condition is characterised by predisposition to benign leiomyomas of the skin and the uterus, renal cell carcinoma (RCC), and uterine leiomyosarcoma (ULMS). To comprehensively examine the cancer risk and tumour spectrum in Finnish FH mutation positive families, genealogical and cancer data were obtained from 868 individuals. The cohort analysis of the standardised incidence ratios (SIR) was analysed from 256 individuals. FH mutation status was analysed from all available individuals (n = 98). To study tumour spectrum in FH mutation carriers, loss of the wild type allele was analysed from all available tumours (n = 22). The SIR was 6.5 for RCC and 71 for ULMS. The overall cancer risk was statistically significantly increased in the age group of 15-29 years, consistent with features of cancer predisposition families in general. FH germline mutation was found in 55% of studied individuals. Most RCC and ULMS tumours displayed biallelic inactivation of FH, as did breast and bladder cancers. In addition, several benign tumours including atypical uterine leiomyomas, kidney cysts, and adrenal gland adenomas were observed. The present study confirms with calculated risk ratios the association of early onset RCC and ULMS with FH germline mutations in Finns. Some evidence for association of breast and bladder carcinoma with HLRCC was obtained. The data enlighten the organ specific malignant potential of HLRCC.

UR - http://www.scopus.com/inward/record.url?scp=33745234207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745234207&partnerID=8YFLogxK

U2 - 10.1136/jmg.2005.036400

DO - 10.1136/jmg.2005.036400

M3 - Article

C2 - 16155190

AN - SCOPUS:33745234207

VL - 43

SP - 523

EP - 526

JO - Journal of Medical Genetics

JF - Journal of Medical Genetics

SN - 0022-2593

IS - 6

ER -